Galmed Pharmaceuticals (NASDAQ:GLMD) announced on April 9, 2026, a significant technological breakthrough with the development of a brain-penetrating formulation of its lead compound, Aramchol.
Co-developed with Barcode Nanotech, the new delivery system utilizes a proprietary lipid nanoparticle (LNP) platform designed to bypass the blood-brain barrier via subcutaneous administration.
The collaboration targets Stearoyl-CoA desaturase 1 (SCD1), an enzyme increasingly recognized as a critical therapeutic target for central nervous system (CNS) disorders.
Specifically, SCD1 inhibition has shown potential in mitigating the aggregation of α-synuclein, the protein responsible for the formation of Lewy bodies in Parkinson’s disease, multiple systems atrophy (MSA), and certain forms of dementia.
Preliminary in vitro data demonstrated that this new formulation effectively down-regulates α-synuclein aggregation in a dose-dependent manner.
Crucially, the studies indicated that the treatment was not associated with cellular toxicity, suggesting a favorable safety profile for further clinical development.
The formulation was optimized using Barcode Nanotech’s AI-based screening platform, which allows for the simultaneous in vivo testing of hundreds of different nanoparticle candidates to identify the most effective vehicle for brain delivery.
This approach aims to solve the historic "delivery barrier" that has hindered nearly 98% of potential CNS drugs from reaching their targets.
Subject to regulatory feedback, Galmed plans to initiate a Phase 1b/2 Proof-of-Concept (PoC) study in patients with Parkinson’s disease in the second half of 2026.
If successful, the therapy could represent a first-in-class disease-modifying treatment, moving beyond the symptomatic relief provided by current standards of care.